** Shares of medtech firm Lensar LNSR.O fall 3.7% to $14.27
** LNSR has agreed to be acquired by Swiss eyecare firm Alcon ALCC.S for $14/shr, totaling around $356 million
** Deal represents a 5.6% discount to LNSR's last close
** U.S.-listed shares of Alcon ALC.N up 1.8% at $92.18
** Alcon may pay Lensar an additional $2.75/shr, totaling up to $430 million, if certain procedure targets are met
** Deal is expected to close in mid-to-late 2025
** LNSR up more than four-fold and U.S.-listed shares of ALC up 7.9% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。